Brii Biosciences' (HKG:2137) said a group of phase 2 trial enrollees of a chronic hepatitis B treatment plan showed immune responsiveness after taking the company's BRII-179 drug, according to a Thursday filing with the Hong Kong bourse.
The data from cohort 4 of the study are "encouraging," Chief Medical Officer David Margolis said during the presentation of data during a congress in Amsterdam, the Netherlands.
The trial assessed the efficacy of the drug, together with a combination of elebsiran and pegylated interferon alpha in patients with chronic hepatitis B, the filing said.
"We saw in target populations that patients who were immune-responsive through pre-treatment with BRII-179 demonstrated a significant advantage in achieving a higher HBsAg seroclearance rate," said Margolis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.